Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2 [0.03%]
WO 2012/177618 A1 和 US-2014/0179750 A1 的评估：新型小分子EP2受体拮抗剂的开发
Thota Ganesh
Thota Ganesh
Recent studies underscore that prostaglandin-E2 exerts mostly proinflammatory effects in chronic CNS and peripheral disease models, mainly through a specific prostanoid receptor EP2. However, very few highly characterized EP2 receptor antag...
A Key Opinion Leader interview: insight into the research and career of Prof. Claudiu T Supuran [0.03%]
走近科研大家：Claudiu T. Supuran教授访谈录
Claudiu T Supuran,Claudia Palmer
Claudiu T Supuran
Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1) [0.03%]
用于治疗分枝杆菌感染的化合物:一项专利评估(WO2014049107A1)
Dany Pechalrieu,Marie Lopez
Dany Pechalrieu
Tuberculosis is one of the main causes of mortality with 1.5 million deaths a year worldwide. The growing emergence of multi- and extremely resistant strains highlights the urgent need of novel antibiotic strategies. Ethionamide, interferin...
Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease [0.03%]
针对37/67kDa层粘连蛋白受体的新型专利治疗策略用于癌症和阿尔茨海默病的治疗
Katarina Jovanovic,Carryn J Chetty,Thandokuhle Khumalo et al.
Katarina Jovanovic et al.
Introduction: The 37/67 kDa high-affinity laminin receptor (laminin receptor precursor/laminin receptor, LRP/LR) is a multi-faceted cellular receptor. It plays a vital role in the malignancy of various cancer types where ...
Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review [0.03%]
阿兹海默氏症脑中类淀粉蛋白-β沉积物影像化合物专利综述
Peiyu Tu,Hualong Fu,Mengchao Cui
Peiyu Tu
Introduction: β-amyloid (Aβ) plaques in the brain are regarded as a hallmark of Alzheimer's disease (AD), and the imaging of Aβ is a critical step for early diagnosis. Extensive research has been done to develop probes...
Natural product-based therapeutics for the treatment of cancer stem cells: a patent review (2010 - 2013) [0.03%]
基于天然产物的癌症干细胞治疗药物专利回顾（2010-2013）
Chien-Hsing Lee,Chung-Yi Chen
Chien-Hsing Lee
Introduction: Cancer stem cells (CSCs) are a subpopulation of tumor cells that possess self-renewal and tumor initiation capacity and the ability to give rise to the heterogenous lineages of cancer cells that comprise the...
Stem cells and differentiation--a synoptic review of patents granted since 2009 [0.03%]
干细胞及其分化作用-对2009年以来已获批专利的综述性回顾分析
Poornima Sureshkumar,Sureshkumar Perumal Srinivasan,Karthick Natarajan et al.
Poornima Sureshkumar et al.
Introduction: Innovations in human pluripotent stem cell research and their application in therapeutics have seen a giant leap in the past decade. Patent applications related to human pluripotent stem cell generation, cul...
Minhang Xin
Minhang Xin
Introduction: The hedgehog (Hh) signaling pathway is an important signaling pathway, playing a critical role in regulation of cell growth, development, metastasis and angiogenesis. Aberrant activation of this pathway has ...
3D-printed biological organs: medical potential and patenting opportunity [0.03%]
3D打印生物器官：医学潜力与专利机会
Seung-Schik Yoo
Seung-Schik Yoo
Three-dimensional (3D) bioprinting has emerged as a new disruptive technology that may address the ever-increasing demand for organ transplants. 3D bioprinting offers many technical features that allow for building functional biological tis...
Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy? [0.03%]
莫迪政府是否会屈服于美国和工商界的壓力而改变其支持药物专利权的政策？
Brook K Baker
Brook K Baker
The US has persistently pressured India to adopt US-style patent protections on pharmaceuticals for many years. That pressure has intensified recently because of Indian rules that have blocked patents on medicines widely patented elsewhere ...